A RANDOMIZED PHASE III STUDY OF IBRUTINIB PLUS
OBINUTUZUMAB VERSUS IBRUTINIB PLUS VENETOCLAX AND
OBINUTUZUMAB IN UNTREATED OLDER PATIENTS (65 YEARS OF
AGE) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Please contact us for more information or to learn if you are eligible to participate.
